Company launched the once-daily formulation ASTAGRAF  XL in the U.S. for the indication of prophylaxis of organ  rejection in adult patients receiving a kidney transplant. In Asia & Oceania, sales of Vesicare increased 29.8%,  to ¥3.8 billion. The favorable sales expansion was driven by  growth in South Korea. In EMEA, despite a continuous increase in sales of the  once-daily formulation Advagraf, sales of Prograf (including  Advagraf) through Astellas’ own distribution channels  declined by 1.3%, to  € 530 million on a euro basis, due  primarily to price reductions in each country and the impact  of generic versions. Sales increased by 23.8%, to ¥71.2  billion when converted to yen due to the impact of foreign  exchange rates. Advagraf is sold in 41 countries, and sales  of Advagraf accounted for around 35% of combined sales  of Advagraf and Prograf in the region. In Asia & Oceania, sales grew by 32.1%, to ¥25.0   billion. Sales showed steady growth mainly in China and  South Korea. Prograf XL was launched in Indonesia in  October 2013. Sales in Japan expanded to ¥30.7 billion, a year-on-year  increase of 2.9%. In fiscal 2013, Vesicare’s share in the  OAB treatment market was approximately 43% (on a value  basis). The combined share of Vesicare and Betanis has  reached approximately 60% (on a value basis) and is still  expanding. Owing to the considerable number of potential  subjects in the OAB treatment market, we will work to  increase market penetration of Vesicare and Betanis by  raising public awareness of this condition. In the Americas, sales of VESIcare rose 2.9%, to  US$580 million on a U.S. dollar basis. When converted to  yen, sales grew by 24.2%, to ¥58.1 billion. VESIcare’s  share in the OAB treatment market reached approximately  22% (on a total prescription basis) in fiscal 2013, maintain- ing the position as the leading branded drug. The com- bined share of VESIcare and Myrbetriq has reached  approximately 25% (on a total prescription basis) and is still  expanding. In EMEA, sales of Vesicare were strong, increasing  13.0%, to  € 317 million on a euro basis, while sales grew by  41.7%, to ¥42.7 billion when converted to yen. Vesicare’s  share in the OAB treatment market reached approximately  49% (on a value basis) in fiscal 2013. In EMEA, the drug is marketed under the brand name  Omnic. In fiscal 2013, sales of Omnic through our own  distribution channels rose 0.5%, to  € 145 million on a euro  basis. When converted to yen, sales rose 26.1%, to  ¥19.4 billion. Sales in Japan declined 11.9% to ¥20.2 billion, due primar- ily to the impact of generic drugs; nevertheless, Harnal still  maintained its top position in the alpha-1 blocker market. Harnal/Omnic (Treatment for functional symptoms associated with benign prostatic hyperplasia (BPH)) Vesicare (Overactive bladder (OAB) treatment) Betanis/Myrbetriq/BETMIGA (generic name: mirabegron, OAB treatment) In Japan, sales of Betanis increased to ¥11.6 billion in fiscal  2013, compared with ¥5.3 billion in fiscal 2012. Betanis  sales grew steadily in fiscal 2013, having become eligible  for long-term prescriptions in October 2012. Betanis’ share  of the OAB treatment market reached approximately 16%  (on a value basis) in fiscal 2013. In the U.S., mirabegron was launched in October 2012  under the brand name Myrbetriq. Myrbetriq sales grew  firmly, reaching US$145 million in fiscal 2013, compared  with US$20 million in fiscal 2012, on a U.S. dollar basis.  When converted to yen, sales were ¥14.5 billion, compared  with ¥1.6 billion in fiscal 2012. Myrbetriq’s share of the U.S.  OAB treatment market reached approximately 4% (on a  total prescription basis) in fiscal 2013. Now that around two  years have passed since the launch of Myrbetriq in the  U.S., the product has gained a strong reputation from  urology specialists in terms of both efficacy and safety. In EMEA, mirabegron was launched in the U.K. in Feb- ruary 2013 under the brand name BETMIGA. The distribu- tion of the product has expanded to cover 22 European  countries (as of July, 2014), registering  € 15 million sales in  fiscal 2013 on a euro basis. When converted to yen, sales  were ¥2.1 billion. In the Asia & Oceania region, this product was launched  in Australia in April 2014. Astellas Pharma Inc.  _ Annual Report 2014 88